These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 30907630)

  • 1. Applications of Next-Generation Sequencing in Neoantigen Prediction and Cancer Vaccine Development.
    Lancaster EM; Jablons D; Kratz JR
    Genet Test Mol Biomarkers; 2020 Feb; 24(2):59-66. PubMed ID: 30907630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in personalized neoantigen vaccines for cancer immunotherapy.
    Sun C; Xu S
    Biosci Trends; 2020 Nov; 14(5):349-353. PubMed ID: 32908077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical and clinical development of neoantigen vaccines.
    Li L; Goedegebuure SP; Gillanders WE
    Ann Oncol; 2017 Dec; 28(suppl_12):xii11-xii17. PubMed ID: 29253113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoantigen vaccine: an emerging tumor immunotherapy.
    Peng M; Mo Y; Wang Y; Wu P; Zhang Y; Xiong F; Guo C; Wu X; Li Y; Li X; Li G; Xiong W; Zeng Z
    Mol Cancer; 2019 Aug; 18(1):128. PubMed ID: 31443694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteogenomics offers a novel avenue in neoantigen identification for cancer immunotherapy.
    Ren Y; Yue Y; Li X; Weng S; Xu H; Liu L; Cheng Q; Luo P; Zhang T; Liu Z; Han X
    Int Immunopharmacol; 2024 Dec; 142(Pt A):113147. PubMed ID: 39270345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges targeting cancer neoantigens in 2021: a systematic literature review.
    Chen I; Chen MY; Goedegebuure SP; Gillanders WE
    Expert Rev Vaccines; 2021 Jul; 20(7):827-837. PubMed ID: 34047245
    [No Abstract]   [Full Text] [Related]  

  • 7. The neoantigens derived from transposable elements - A hidden treasure for cancer immunotherapy.
    Hu Z; Guo X; Li Z; Meng Z; Huang S
    Biochim Biophys Acta Rev Cancer; 2024 Sep; 1879(5):189126. PubMed ID: 38849060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computational Prediction and Validation of Tumor-Associated Neoantigens.
    Roudko V; Greenbaum B; Bhardwaj N
    Front Immunol; 2020; 11():27. PubMed ID: 32117226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoantigen prediction and computational perspectives towards clinical benefit: recommendations from the ESMO Precision Medicine Working Group.
    De Mattos-Arruda L; Vazquez M; Finotello F; Lepore R; Porta E; Hundal J; Amengual-Rigo P; Ng CKY; Valencia A; Carrillo J; Chan TA; Guallar V; McGranahan N; Blanco J; Griffith M
    Ann Oncol; 2020 Aug; 31(8):978-990. PubMed ID: 32610166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. pTuneos: prioritizing tumor neoantigens from next-generation sequencing data.
    Zhou C; Wei Z; Zhang Z; Zhang B; Zhu C; Chen K; Chuai G; Qu S; Xie L; Gao Y; Liu Q
    Genome Med; 2019 Oct; 11(1):67. PubMed ID: 31666118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methods behind neoantigen prediction for personalized anticancer vaccines.
    Godazandeh K; Van Olmen L; Van Oudenhove L; Lefever S; Bogaert C; Fant B
    Methods Cell Biol; 2024; 183():161-186. PubMed ID: 38548411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Changing Landscape of Therapeutic Cancer Vaccines-Novel Platforms and Neoantigen Identification.
    Jou J; Harrington KJ; Zocca MB; Ehrnrooth E; Cohen EEW
    Clin Cancer Res; 2021 Feb; 27(3):689-703. PubMed ID: 33122346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Best practices for bioinformatic characterization of neoantigens for clinical utility.
    Richters MM; Xia H; Campbell KM; Gillanders WE; Griffith OL; Griffith M
    Genome Med; 2019 Aug; 11(1):56. PubMed ID: 31462330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoantigen vaccine platforms in clinical development: understanding the future of personalized immunotherapy.
    Supabphol S; Li L; Goedegebuure SP; Gillanders WE
    Expert Opin Investig Drugs; 2021 May; 30(5):529-541. PubMed ID: 33641576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Personalized cancer vaccines: Targeting the cancer mutanome.
    Zhang X; Sharma PK; Peter Goedegebuure S; Gillanders WE
    Vaccine; 2017 Feb; 35(7):1094-1100. PubMed ID: 27449681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engineering neoantigen vaccines to improve cancer personalized immunotherapy.
    Liu Z; Lv J; Dang Q; Liu L; Weng S; Wang L; Zhou Z; Kong Y; Li H; Han Y; Han X
    Int J Biol Sci; 2022; 18(15):5607-5623. PubMed ID: 36263174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low Mutation Burden in Ovarian Cancer May Limit the Utility of Neoantigen-Targeted Vaccines.
    Martin SD; Brown SD; Wick DA; Nielsen JS; Kroeger DR; Twumasi-Boateng K; Holt RA; Nelson BH
    PLoS One; 2016; 11(5):e0155189. PubMed ID: 27192170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunopharmacogenomics towards personalized cancer immunotherapy targeting neoantigens.
    Kiyotani K; Chan HT; Nakamura Y
    Cancer Sci; 2018 Mar; 109(3):542-549. PubMed ID: 29288513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Neoantigens and Whole-Exome Sequencing].
    Karasaki T; Nakajima J; Kakimi K
    Gan To Kagaku Ryoho; 2016 Jul; 43(7):791-7. PubMed ID: 27431622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer neoantigen: Boosting immunotherapy.
    Xu P; Luo H; Kong Y; Lai WF; Cui L; Zhu X
    Biomed Pharmacother; 2020 Nov; 131():110640. PubMed ID: 32836075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.